The ATEMPT trial compared adjuvant treatment in HER2-positive breast cancer with paclitaxel plus trastuzumab versus TDM-1 (ado-trastuzumab emtansine, an antibody–drug conjugant). The gene discussed is ERBB2; the disease is breast carcinoma.